Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190018/S050

Clareon Vivity Pro Extended Vision IOLs

Alcon Laboratories, LLC · Decision date Oct 30, 2026

MEDTECHLEDGER EXPLANATIONP190018/S050

What did the FDA approve?

The FDA recorded an approval decision on 2026-10-30 for PMA supplement P190018/S050, submitted by Alcon Laboratories, LLC under the Normal 180 Day Track. The supplement reason is a change to design, components, specifications or material, so the action covers the modified extended depth of focus intraocular lens (product code POE, ophthalmic specialty) rather than a fresh approval of the underlying system.

The approval statement lists eight Clareon Vivity Pro Extended Vision configurations: non-toric and toric versions, each with and without UV-absorbing designation, and each with and without the AutonoMe pre-loaded delivery system. The source record includes no documents, so the specific design or material changes, and any clinical data supporting them, are not described here and remain unknown.

FDA approval order statement

approval for the Clareon Vivity Pro Extended Vision IOLs, Clareon Vivity Pro Extended Vision Toric IOLs, Clareon Vivity Pro Extended Vision UV Absorbing IOL, Clareon Vivity Pro Extended Vision Toric UV Absorbing IOLs, Clareon Vivity Pro Extended Vision IOL with the AutonoMe Pre-loaded Delivery System, Clareon Vivity Pro Extended Vision Toric IOLs with the AutonoMe Pre-loaded Delivery System, Clareon Vivity Pro Extended Vision UV Absorbing IOL with the AutonoMe Pre-loaded Delivery System, and Clareon Vivity Pro Extended Vision Toric UV Absorbing IOLs with the AutonoMe Pre-loaded Delivery System
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Ophthalmic
Decision date
Oct 30, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P190018/S050
Regulatory pathway
PMA supplement
Product code
POE
Decision code
APPR
Decision date
Oct 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Extended depth of focus intraocular lens.

Product code
POE
FDA device class
3

For the original device and its historical approval scope, see PMA P190018. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P190018 · Original PMA

    Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL), Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lens

  2. P190018/S050 received

    Application receipt date recorded by FDA.

  3. P190018/S050 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P190018. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190018

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Alcon Laboratories, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6201 S. Fwy., Fort Worth, TX, 76134

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records